BC3402

DRUG2 trials

Sponsors

Biocity Biopharmaceutics Co., Ltd., Case Comprehensive Cancer Center

Conditions

Chronic Myelomonocytic LeukemiaHepato Cellular Carcinoma (HCC)Myelodysplastic Syndromes

Phase 1

Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML

Biocity Biopharmaceutics Co., Ltd.Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes

Start: 2023-06-18End: 2025-12-31Target: 32Updated: 2023-08-01

BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma

WithdrawnNCT06608940

Case Comprehensive Cancer CenterHepato Cellular Carcinoma (HCC)

Start: 2025-11-01End: 2028-01-01Updated: 2026-02-19

Related Papers

An Open-Label, Multicenter, Phase Ib Study of the Anti-TIM3 Monoclonal Antibody BC3402 in Combination with Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Blood2024-11-05